Jubilant Biosys Limited. Jubilant Biosys Doubles Early Chemistry Scale-Up Capacity with New Noida Facility in India. Press ...
About the FALCON Trial FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability of SGT-212 in participants aged 18-40 who have been ...
SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations -- Dosing of the first participant in the Phase 1b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback